Clinical trials: Patients Eligible for Tumor Biopsy
Melanoma
Gene Expression Profiles and ctDNA for Risk Stratification in Patients With Melanoma
This study aims at assessing the role of MerlinTM and ctDNA in predicting the nodal status in patients with >pT3b melanoma, therefore candidate for adjuvant therapy regardless of sentinel lymph node status.
- Trial name
- CORRESPOND (NCT06566404)
- Volunteers
- 200 people
- Sponsor
- European Institute of Oncology
Ductal Carcinoma in Situ
Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates
This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to…
- Trial name
- NCT05961280
- Testing
- Mastectomy with sentinel lymph node biopsy
- Volunteers
- 385 people
- Sponsor
- Gangnam Severance Hospital
Prostate Cancer
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or…
- Trial name
- NCT03187990
- Testing
- [68Ga]PSMA-11, [18F]PSMA-1007
- Where
- Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Irene Burger
Melanoma, Skin, Adjuvant Treatment
One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy
Melanoma is one of the most aggressive solid cancers, although mortality can be reduced with early treatment. Immunotherapy has transformed the prognosis of this pathology.
- Trial name
- MELASENTI (NCT06809491)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Central Hospital, Nancy, France
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
This randomized pilot early phase I trial studies the side effects and how well nivolumab alone works compared to nivolumab with bevacizumab or ipilimumab before surgery in treating patients with kidney cancer, also referred to…
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02210117
- Testing
- Bevacizumab, Biopsy, Ipilimumab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
This is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential eligibility for a biomarker selected clinical trial…
- Conditions
- Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation
- Trial name
- NCT04698681
- Where
- 63 sites in United States
- Volunteers
- 20 people
- Sponsor
- Calithera Biosciences, Inc
Patients That Have Been Diagnosed With Colorectal Cancer, Patients Eligible for Tumor Biopsy
NovellusDx Tissue Collection Protocol
NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.
- Trial name
- NCT01791322
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Fore Biotherapeutics